← Back to patent-cliff list
萘替芬酮康唑
Tier C — Watch / tradeNaftifine hydrochloride/Ketoconazole
重庆华邦制药有限公司
Originator
2005
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：Ergosterol、CYP51A1
Brand：必亮
Indications (approved)：真菌感染
Regional status
US
-
EU
-
China
批准上市
2005-09-26
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Naftifine hydrochloride/Ketoconazole?
Approved indications include: 真菌感染.
When does the Naftifine hydrochloride/Ketoconazole patent expire?
No public expiry year is available for Naftifine hydrochloride/Ketoconazole yet; this page updates once verified.
How do I get a quote for Naftifine hydrochloride/Ketoconazole intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24